Compare GSK plc (GSK) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Upwork Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Upwork Inc trades at $8.6 (market cap $1.07B). The key difference: GSK plc is far larger — about 85.9× Upwork Inc's market cap, and GSK plc pays a 3.9% dividend while Upwork Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Upwork Inc for 38 Days on average.
| GSK | UPWK | |
|---|---|---|
Market Cap | $91.88B | $1.07B |
Volume | 7,730,529 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $61.18 | $22.11 |
52-Week Low | $43.24 | $7.84 |
Typical Hold Time | 93 Days | 38 Days |
Enterprise Value | $111.88B | $833.01M |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Upwork (UPWK) trades at $8.60, up 2.38% today, with a bearish technical signal despite recent earnings beat. The stock shows strong fundamentals with 77.21% gross margins and 12.93% net income margin, though revenue growth has stalled at $788M in 2025. Recent insider selling and ongoing securities fraud investigations create headwinds, while institutional buying from Bank of America provides some support. Technical indicators show resistance at $9 and support at $8.
The stock presents a mixed outlook with attractive valuation metrics (P/E 10.99, P/S 1.48) but faces significant AI disruption risks and declining active clients. Analyst consensus leans bullish with $9.64 price target, though near-term challenges from weak guidance and legal scrutiny may limit upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
